Noema Pharma

About

Noema Pharma is a clinical-stage biotech company focused on developing innovative therapeutics for central nervous system (CNS) conditions. Founded in 2019, the company operates in both the United States and Switzerland, with its headquarters in Basel. Noema Pharma aims to address both orphan and larger patient populations suffering from debilitating brain and nervous system disorders. The company has four programs currently in active Phase II clinical trials, targeting conditions such as seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette Syndrome, and vasomotor symptoms related to menopause. Notably, its investigational therapies include Gemlapodect (NOE-105) for Tourette Syndrome and Cendifensine for menopause-related symptoms. Noema Pharma collaborates with patients, families, and healthcare professionals to ensure that their experiences and needs are integrated into the development of its therapies.